Analgesics Groupstypes Subtypesmoa Indications And Contraindications

Educational clinical summary of Analgesics Groupstypes Subtypesmoa Indications And Contraindications for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This document provides comprehensive medical information for educational and reference purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment and consider individual patient circumstances, local guidelines, and the latest evidence when making patient care decisions. Dosages and recommendations are for typical adult populations and may require adjustment for special populations or comorbidities.

Overview

Definition: Analgesics are a diverse group of pharmacological agents used to relieve pain (analgesia) without causing loss of consciousness. They act through various mechanisms to reduce the perception of pain, inhibit pain signal generation, or modulate pain pathways in the central nervous system.
Epidemiology: Pain is a widespread global health issue, with chronic pain affecting approximately 20-30% of the adult population in many countries, and acute pain being a common complaint in clinical practice (e.g., post-operative pain, injury-related pain). Analgesics are among the most frequently prescribed and over-the-counter medications worldwide. Misuse, abuse, and dependence are significant public health concerns, particularly with opioid analgesics.
Classification: Analgesics can be broadly classified based on their chemical structure, primary mechanism of action, or the type/severity of pain they typically treat.

Major Groups of Analgesics:
1. Non-Opioid Analgesics:
  - Acetaminophen (Paracetamol)
  - Nonsteroidal Anti-inflammatory Drugs (NSAIDs):
    - Traditional (non-selective COX inhibitors)
    - COX-2 selective inhibitors
2. Opioid Analgesics:
  - Weak Opioids: (e.g., codeine, tramadol)
  - Strong Opioids: (e.g., morphine, oxycodone, hydromorphone, fentanyl)
  - Partial Opioid Agonists/Antagonists: (e.g., buprenorphine)
  - Opioid Antagonists: (e.g., naloxone, naltrexone)
3. Adjuvant Analgesics (Co-analgesics): Medications primarily indicated for other conditions but possess analgesic properties, often used for specific types of pain (e.g., neuropathic pain).
  - Antidepressants (Tricyclic Antidepressants - TCAs, Serotonin-Norepinephrine Reuptake Inhibitors - SNRIs)
  - Anticonvulsants (Gabapentinoids: gabapentin, pregabalin)
  - Corticosteroids
  - Skeletal Muscle Relaxants
  - Topical Analgesics (Lidocaine, Capsaicin)
  - N-methyl-D-aspartate (NMDA) receptor antagonists (e.g., ketamine)
  - Alpha-2 Adrenergic Agonists (e.g., clonidine, tizanidine)
4. Emerging Therapies: Cannabinoids, nerve growth factor inhibitors (e.g., tanezumab), voltage-gated sodium channel blockers.

Pathophysiology

Mechanism (of Pain & Analgesic Action):
- Pain Physiology: Pain involves a complex interplay of nociception (the encoding of noxious stimuli), sensory processing in the spinal cord, and higher cortical interpretation.
  - Nociceptive Pain: Arises from actual or threatened damage to non-neural tissue and is due to the activation of nociceptors (e.g., somatic pain from musculoskeletal injury, visceral pain from organ distension).
  - Neuropathic Pain: Caused by a lesion or disease of the somatosensory nervous system (e.g., diabetic neuropathy, post-herpetic neuralgia, sciatica).
  - Nociplastic Pain (formerly Central Sensitization Pain): Pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence of disease or lesion of the somatosensory system causing the pain (e.g., fibromyalgia, irritable bowel syndrome).
- Analgesic Mechanisms:
  - Non-Opioids (Acetaminophen/NSAIDs): Primarily act peripherally and centrally. NSAIDs inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis (which sensitize nociceptors). Acetaminophen's exact MOA is not fully understood but involves central COX inhibition, serotonergic pathways, and cannabinoid systems.
  - Opioids: Bind to opioid receptors (mu, kappa, delta) in the central nervous system (brain, spinal cord) and peripheral tissues. Mu-receptor agonism is primarily responsible for analgesia, euphoria, and respiratory depression. They inhibit neurotransmitter release from presynaptic terminals and hyperpolarize postsynaptic neurons, thereby reducing pain signal transmission.
  - Adjuvant Analgesics:
    - Antidepressants (TCAs, SNRIs): Increase levels of norepinephrine and serotonin in descending pain inhibitory pathways in the spinal cord.
    - Anticonvulsants (Gabapentinoids): Bind to the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters involved in pain signaling, particularly in neuropathic pain.
    - Corticosteroids: Reduce inflammation and swelling, which can alleviate pain from nerve compression or inflammatory conditions.
    - NMDA Receptor Antagonists: Block the NMDA receptor, preventing central sensitization and reducing neuropathic and acute severe pain.
Risk Factors (for pain and adverse effects of analgesics):
- For Pain: Chronic medical conditions (e.g., arthritis, cancer, diabetes), acute injury/trauma, surgery, psychiatric comorbidities (e.g., depression, anxiety), genetic predispositions, advanced age, socio-economic factors.
- For Analgesic Adverse Effects:
  - NSAIDs: History of peptic ulcer disease, gastrointestinal bleeding, renal impairment, cardiovascular disease (hypertension, heart failure, history of MI/stroke), advanced age, concomitant anticoagulant use.
  - Acetaminophen: Hepatic impairment, chronic alcohol use, malnutrition.
  - Opioids: History of substance use disorder, respiratory compromise (e.g., COPD, sleep apnea), advanced age, renal/hepatic impairment, concomitant use of CNS depressants (benzodiazepines, alcohol), psychiatric disorders.
  - Adjuvants: Specific to the drug class (e.g., cardiac disease for TCAs, renal impairment for gabapentinoids).
Protective Factors: Early and appropriate pain assessment, multimodal analgesia strategies, patient education, regular monitoring for efficacy and adverse effects, adherence to prescribing guidelines, and non-pharmacological interventions.

Clinical Presentation (Related to Pain Assessment and Analgesic Efficacy/Safety)

Signs and Symptoms

Cardinal Features (of Pain): Subjective experience of discomfort.
- Location: Where the pain is felt.
- Intensity: Severity, often rated on a scale (e.g., 0-10 Numeric Rating Scale, Visual Analog Scale).
- Quality: Descriptive terms (e.g., sharp, dull, throbbing, burning, aching, shooting, crushing).
- Onset and Duration: When it started, how long it lasts, constant vs. intermittent.
- Timing: When it is worse (e.g., morning stiffness, night pain).
- Aggravating/Alleviating Factors: What makes it worse or better.
- Associated Symptoms: Nausea, fatigue, mood changes, functional limitations.
Early Signs (of Analgesic Adverse Effects):
- NSAIDs: Dyspepsia, heartburn, nausea.
- Acetaminophen: Often asymptomatic until severe liver injury.
- Opioids: Sedation, constipation, nausea, pruritus, mild dizziness.
- Gabapentinoids: Drowsiness, dizziness, ataxia.
Advanced Signs (of Analgesic Adverse Effects):
- NSAIDs: Melena/hematemesis (GI bleed), oliguria/anuria (renal failure), chest pain/dyspnea (cardiovascular event).
- Acetaminophen: Jaundice, right upper quadrant pain, encephalopathy (liver failure).
- Opioids: Severe respiratory depression (bradypnea, shallow breathing), pinpoint pupils, unresponsiveness (overdose), severe constipation with impaction, opioid-induced hyperalgesia (paradoxical increase in pain).
- Antidepressants (TCAs): Arrhythmias, dry mouth, urinary retention, orthostatic hypotension.
Atypical Presentations:
- Pain: Referred pain, pain out of proportion to injury, pain with minimal physical findings (suggesting neuropathic or nociplastic components).
- Analgesic Effects: Idiosyncratic reactions, paradoxical effects (e.g., agitation with opioids in some elderly patients), unexpected drug-drug interactions.

Physical Examination (Relevant to Pain Assessment and Analgesic Safety)

Inspection:
- Observe posture, gait, guarding, facial expressions of pain.
- Skin changes: rashes (allergic reaction), jaundice (liver injury).
- Respiratory rate and pattern (opioid overdose).
- Pupil size (miosis with opioids).
Palpation:
- Tenderness, swelling, warmth at site of pain.
- Abdominal tenderness (e.g., GI bleed).
Special Tests:
- Neurological examination for sensory/motor deficits (neuropathic pain).
- Range of motion testing.
- Specific orthopedic tests (e.g., straight leg raise for sciatica).
- Pain provocation tests.

Diagnostic Approach (for Pain Assessment and Analgesic Selection)

History Taking

Key Questions:
- PQRST assessment of pain: Precipitating/Palliating factors, Quality, Region/Radiation, Severity, Timing.
- Impact on Function: ADLs, sleep, mood, work, social life.
- Past Pain History: Previous treatments, efficacy, side effects.
- Medical Comorbidities: Renal, hepatic, cardiovascular disease, psychiatric history.
- Medication History: Current medications (prescription, OTC, herbal), allergies, drug-drug interaction potential.
- Social History: Alcohol, tobacco, illicit drug use (risk for opioid misuse).
- Psychosocial Factors: Stress, depression, anxiety, coping mechanisms.
- Goals of Pain Management: What constitutes acceptable pain relief for the patient.
Red Flags (indicating serious underlying pathology or analgesic adverse event):
- Pain: Acute severe pain, pain with neurological deficit (weakness, numbness, bowel/bladder dysfunction), fever/chills (infection), unexplained weight loss (malignancy), pain worsened by Valsalva (radiculopathy), pain unresponsive to usual analgesia.
- Analgesic Adverse Events: Signs of GI bleeding (melena, hematemesis), severe shortness of breath, altered mental status, signs of anaphylaxis (hives, angioedema, hypotension).

Laboratory Tests

First-Line:
- Complete Blood Count (CBC): Baseline, monitor for anemia (GI bleeding from NSAIDs).
- Renal Function (BUN, Creatinine, eGFR): Before initiating NSAIDs, gabapentinoids, opioids; monitor for renal impairment.
- Liver Function Tests (ALT, AST, Bilirubin): Before initiating acetaminophen, NSAIDs, some adjuvants; monitor for hepatic toxicity.
Confirmatory:
- Drug Levels: Rarely indicated for common analgesics, except in suspected toxicity (e.g., acetaminophen levels in overdose) or to guide therapy for some adjuvants (e.g., tricyclic antidepressant levels).
- Urine Drug Screens: In chronic opioid therapy, to monitor for adherence or detect illicit substance use.
Monitoring:
- Regular monitoring of renal and liver function, especially with chronic NSAID or high-dose acetaminophen use, and in patients with baseline impairment.
- Electrolytes (e.g., with diuretic use or in renal impairment).

Imaging (Primarily for diagnosing the cause of pain)

Recommended:
- X-rays: For suspected fracture, degenerative joint disease, spinal alignment issues.
- MRI: For suspected radiculopathy, spinal cord compression, soft tissue injury, complex joint pathology.
- CT Scan: For complex fractures, abdominal pathology, intracranial pathology.
Advanced:
- Bone Scan: For metastatic disease, occult fractures, osteomyelitis.
- Nerve Conduction Studies/EMG: To confirm and characterize neuropathic pain.

Management

Acute Management (of Pain)

Immediate:
- Rapid pain assessment (intensity, location, type).
- Initiate multimodal analgesia: Often involves a combination of non-opioids, regional anesthesia, and opioids, aiming to optimize pain relief while minimizing side effects.
- Consider nerve blocks for localized severe pain.
Stabilization:
- Establish IV access if IV medications are needed.
- Monitor vital signs, especially respiratory rate and sedation level with opioids.
- Address associated symptoms (e.g., antiemetics for nausea).
Emergency:
- Opioid Overdose: Administer Naloxone (opioid antagonist) 0.4-2 mg IV/IM/SC/intranasal; repeat every 2-3 minutes as needed. Monitor for re-sedation.
- Anaphylaxis: Epinephrine 0.3-0.5 mg IM.
- Severe GI Bleeding (from NSAIDs): Fluid resuscitation, blood transfusion, proton pump inhibitors, endoscopy.
- Acetaminophen Overdose: Administer N-acetylcysteine (NAC) IV or oral, based on serum acetaminophen levels and time from ingestion.

Chronic Management (of Pain with Analgesics)

Pharmacological:
- WHO Analgesic Ladder (Modified): A stepped approach to pain management, traditionally for cancer pain, but adaptable for chronic non-cancer pain.
  - Step 1 (Mild Pain): Non-opioid analgesics (Acetaminophen, NSAIDs) +/- Adjuvants.
  - Step 2 (Moderate Pain): Weak opioids (e.g., codeine, tramadol) + Non-opioid analgesics +/- Adjuvants.
  - Step 3 (Severe Pain): Strong opioids (e.g., morphine, oxycodone, fentanyl) + Non-opioid analgesics +/- Adjuvants.
- Specific Drug Classes (Detailed):
  1. Acetaminophen (Paracetamol)
    - MOA: Central COX inhibition, serotonergic pathways, cannabinoid systems. Primarily antipyretic and analgesic.
    - Indications: Mild to moderate pain, fever. Often used as a first-line agent or in multimodal regimens.
    - Typical Adult Dosage: 325-1000 mg every 4-6 hours PRN. Max 4000 mg/24 hours (some recommend max 3000 mg/24 hours for chronic use or risk factors).
    - Contraindications: Severe hepatic impairment, known hypersensitivity.
    - Precautions: Alcoholism, malnutrition, pre-existing liver disease.
  2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    - MOA: Inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. COX-1 is constitutive (gastric protection, platelet aggregation, renal blood flow), COX-2 is inducible (inflammation, pain).
    - Indications: Mild to moderate pain (e.g., musculoskeletal, headache, dysmenorrhea), inflammatory conditions (e.g., arthritis), fever.
    - Types & Examples:
      - Traditional (Non-selective COX inhibitors): Ibuprofen, naproxen, diclofenac, ketorolac.
        
        Ibuprofen Dosage: 200-800 mg every 6-8 hours. Max 3200 mg/24 hours (OTC max 1200 mg/24 hours).
        
        Naproxen Dosage: 250-500 mg every 8-12 hours. Max 1250 mg/24 hours (first day), then 1000 mg/24 hours.
        
        Ketorolac (short-term only, max 5 days): IV 15-30 mg every 6 hours; Oral 10 mg every 4-6 hours. Max 40 mg/24 hours.
      - COX-2 Selective Inhibitors: Celecoxib.
        
        Celecoxib Dosage: 100-200 mg once or twice daily.
    - Contraindications:
      - Absolute: Active peptic ulcer, GI bleeding, severe renal impairment (CrCl <30 mL/min), severe heart failure, peri-operative pain in CABG surgery (COX-2 inhibitors), aspirin-exacerbated respiratory disease (AERD).
      - Relative: Hypertension, cardiovascular disease, elderly.
    - Precautions: Concurrent anticoagulants/antiplatelets, history of GI events, hypertension.
  3. Opioid Analgesics
    - MOA: Agonism at opioid receptors (primarily mu-opioid receptor) in CNS and periphery, inhibiting pain signal transmission.
    - Indications: Moderate to severe acute and chronic pain.
    - Types & Examples:
      - Weak Opioids:
        
        Codeine: Prodrug, converted to morphine. Often combined with acetaminophen.
        
        Dosage: 15-60 mg every 4-6 hours. Max 360 mg/24 hours.
        
        Contraindications: Ultrafast metabolizers (CYP2D6), severe respiratory depression, children <12 years.
        
        Tramadol: Weak mu-opioid agonist, inhibits reuptake of norepinephrine and serotonin.
        
        Dosage: 50-100 mg every 4-6 hours. Max 400 mg/24 hours.
        
        Contraindications: History of seizures (lowers seizure threshold), concomitant use of SSRIs/SNRIs (serotonin syndrome risk), severe respiratory depression.
      - Strong Opioids (Examples of typical adult dosages/equivalencies - highly individualized):
        
        Morphine: Prototypical opioid. Oral 15-30 mg every 3-4 hours; IV 2-10 mg every 3-4 hours. Oral Morphine Equivalent (OME) is reference (1:1).
        
        Oxycodone: Oral 5-20 mg every 4-6 hours. OME conversion factor: ~1.5 (oral oxycodone to oral morphine).
        
        Hydromorphone: Oral 2-8 mg every 3-4 hours; IV 0.5-2 mg every 3-4 hours. OME conversion factor: ~5 (oral hydromorphone to oral morphine).
        
        Fentanyl: Transdermal patch (e.g., 25 mcg/hr, equivalent to ~60-90 mg oral morphine/24 hours). IV 25-100 mcg. Not for opioid-naïve patients.
        
        Methadone: Complex pharmacokinetics, long half-life, NMDA receptor antagonist properties. Requires specialist supervision.
    - Contraindications (for Strong Opioids): Severe respiratory depression, acute or severe bronchial asthma (in unmonitored settings), known or suspected paralytic ileus, hypersensitivity, opioid naïve patients for long-acting/high-potency formulations.
    - Precautions: Head injury, increased intracranial pressure, respiratory compromise, renal/hepatic impairment, elderly, addiction risk, concomitant CNS depressants.
      - Opioid-induced constipation: Prophylaxis with stool softener and stimulant laxative is essential.
      - Opioid Use Disorder (OUD): Assess risk, monitor, refer for treatment if needed.
  4. Adjuvant Analgesics
    - Antidepressants (e.g., Amitriptyline, Duloxetine):
      - MOA: Block reuptake of norepinephrine and serotonin, strengthening descending pain inhibitory pathways. TCAs also have anticholinergic effects.
      - Indications: Neuropathic pain, chronic low back pain, fibromyalgia, chronic headache.
      - Amitriptyline (TCA) Dosage: Start low (e.g., 10-25 mg at bedtime), titrate slowly to 50-150 mg/day.
      - Duloxetine (SNRI) Dosage: 30-60 mg daily (max 120 mg/day).
      - Contraindications (TCAs): Recent MI, severe heart block, glaucoma, urinary retention. Contraindications (SNRIs): MAOI use, severe hepatic impairment.
    - Anticonvulsants (e.g., Gabapentin, Pregabalin):
      - MOA: Bind to alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release.
      - Indications: Neuropathic pain (e.g., post-herpetic neuralgia, diabetic neuropathy), fibromyalgia.
      - Gabapentin Dosage: Start 100-300 mg at bedtime, titrate to 900-3600 mg/day in 3 divided doses. Renal adjustment required.
      - Pregabalin Dosage: Start 50-75 mg BID-TID, titrate to 150-300 mg BID. Max 600 mg/day. Renal adjustment required.
      - Contraindications: Hypersensitivity.
      - Precautions: Renal impairment, history of substance abuse.
    - Topical Analgesics (e.g., Lidocaine patch, Capsaicin cream):
      - MOA: Lidocaine blocks sodium channels, stabilizing neuronal membranes. Capsaicin depletes Substance P.
      - Indications: Localized neuropathic pain, musculoskeletal pain.
      - Lidocaine 5% Patch: Apply to affected area for 12 hours on, 12 hours off. Max 3 patches at one time.
      - Capsaicin 0.025-0.1% Cream: Apply TID-QID. Can cause initial burning sensation.
      - Contraindications: Hypersensitivity, broken skin.
Non-pharmacological: Crucial for chronic pain management.
- Physical Therapy/Occupational Therapy: Exercise, modalities, functional restoration.
- Cognitive Behavioral Therapy (CBT): Addresses maladaptive thoughts and behaviors related to pain.
- Mindfulness-Based Stress Reduction: Improves coping and reduces pain perception.
- Interventional Pain Procedures: Nerve blocks, epidural injections, radiofrequency ablation, spinal cord stimulation.
- Acupuncture, Massage, Chiropractic Care.
- Lifestyle Modifications: Weight management, smoking cessation, healthy diet, sleep hygiene.
Monitoring:
- Efficacy: Regular assessment of pain intensity (e.g., using NRS), functional improvement, quality of life.
- Adverse Effects: Routine questioning and screening for common side effects (GI, renal, cardiovascular, CNS, respiratory depression, constipation).
- Aberrant Drug-Taking Behavior: Tools like Opioid Risk Tool (ORT), urine drug screens, Prescription Drug Monitoring Programs (PDMPs) for chronic opioid therapy.
- Specific Monitoring: Renal/hepatic function, blood pressure, mental status, respiratory status.

Treatment Algorithms

First-Line:
- Acute Mild-Moderate Pain: Acetaminophen or NSAIDs.
- Acute Severe Pain: Short-acting opioids (titrated to effect) or multimodal approach including regional anesthesia.
- Chronic Nociceptive Pain: Acetaminophen, NSAIDs (judiciously), then weak opioids, then strong opioids per WHO ladder. Consider adjunctive therapies for specific components (e.g., muscle relaxants for spasm).
- Chronic Neuropathic Pain: Gabapentinoids (gabapentin, pregabalin) or SNRIs (duloxetine, venlafaxine) or TCAs (amitriptyline, nortriptyline).
Second-Line:
- Pain not controlled by first-line: Escalation on WHO ladder, switching within a drug class, adding an adjuvant, or switching adjuvants.
- Neuropathic Pain: Combination of anticonvulsants and antidepressants, topical agents, tramadol, or strong opioids (last resort for severe, refractory neuropathic pain).
Refractory Cases:
- Referral to a specialized pain management clinic.
- Interventional procedures (e.g., spinal cord stimulator, intrathecal drug delivery).
- Comprehensive pain rehabilitation programs.
- Psychological support and treatment for co-occurring mental health disorders.

Complications (of Analgesic Use)

Common:
- NSAIDs: Dyspepsia, heartburn, nausea, abdominal pain, fluid retention.
- Acetaminophen: Nausea, vomiting (especially in overdose).
- Opioids: Constipation, nausea, vomiting, sedation, dizziness, pruritus, dry mouth, urinary retention.
- Gabapentinoids: Drowsiness, dizziness, ataxia.
- TCAs: Dry mouth, constipation, blurred vision, urinary retention, orthostatic hypotension, sedation.
- SNRIs: Nausea, insomnia, sweating, dizziness, hypertension.
Serious:
- NSAIDs: Gastrointestinal bleeding/perforation, acute kidney injury (AKI), cardiovascular thrombotic events (MI, stroke), exacerbation of heart failure, anaphylaxis.
- Acetaminophen: Fulminant hepatic failure (especially with overdose or chronic high doses).
- Opioids:
  - Respiratory depression: Life-threatening, especially in overdose or with concomitant CNS depressants.
  - Opioid Use Disorder (OUD): Addiction, dependence, withdrawal syndrome.
  - Opioid-induced hyperalgesia (OIH): Paradoxical increase in pain sensitivity.
  - Serotonin Syndrome: With tramadol, meperidine, and concomitant serotonergic agents.
  - Adrenal insufficiency, hypogonadism.
- TCAs: Cardiac arrhythmias (Q-T prolongation), seizures, severe anticholinergic effects.
- SNRIs: Serotonin syndrome, blood pressure elevation.
- Gabapentinoids: Sedation leading to falls, respiratory depression (especially with opioids).
Long-term:
- NSAIDs: Chronic kidney disease, cardiovascular disease progression, peptic ulcer disease.
- Opioids: Chronic constipation, endocrine dysfunction (hypogonadism, decreased bone density), immune modulation, tolerance, physical dependence, psychological dependence (addiction).
- Adjuvants: Weight gain (TCAs, gabapentinoids), cognitive impairment (some TCAs in elderly), sexual dysfunction (antidepressants).

Prognosis (Related to Pain Management)

Factors Affecting Outcome: Type and etiology of pain (acute vs. chronic, nociceptive vs. neuropathic), severity, comorbidities (physical and psychiatric), psychosocial factors, adherence to treatment plan, access to care, and appropriateness of analgesic selection and monitoring.
Survival: Analgesics themselves do not directly impact survival, but appropriate pain management can improve quality of life and functional status. Conversely, complications from analgesic use (e.g., opioid overdose, NSAID-induced GI bleed) can be life-threatening.
Quality of Life: A primary outcome measure in chronic pain management. Effective analgesia and functional restoration can significantly improve physical activity, sleep, mood, social engagement, and overall well-being.

Prevention (of Analgesic-Related Harms)

Primary:
- Appropriate Prescribing: Use the lowest effective dose for the shortest duration necessary. Avoid opioids for mild pain.
- Risk Stratification: Identify patients at high risk for adverse effects (e.g., GI bleed, AKI, OUD).
- Patient Education: Inform patients about proper use, potential side effects, safe storage, and disposal of medications.
- Multimodal Analgesia: Minimize reliance on a single analgesic class, especially opioids.
- Non-pharmacological First: Advocate for non-pharmacological therapies where appropriate.
Secondary:
- Monitoring: Regular clinical assessment and laboratory monitoring for adverse effects (e.g., renal/hepatic function, GI symptoms, sedation, respiratory status).
- Prescription Drug Monitoring Programs (PDMPs): Mandated use for opioid prescribing in many regions to identify potential misuse or diversion.
- Early Intervention: For signs of dependence or aberrant drug-taking behavior, initiate dose reduction, discontinuation, or referral to addiction specialists.
- Prophylaxis: PPIs for high-risk NSAID users, bowel regimen for opioid users.
Tertiary:
- Treatment of Complications: Management of GI bleeds, AKI, opioid overdose (naloxone), OUD (medication-assisted treatment like buprenorphine/naloxone, methadone).
- Pain Rehabilitation Programs: For complex chronic pain and those with OUD.

Special Populations

Pediatric:
- Weight-based dosing: Essential for all analgesics.
- Specific formulations: Liquid or chewable options.
- Caution with NSAIDs: Risk of Reye's syndrome with aspirin in viral infections. Ibuprofen, naproxen generally safe.
- Opioids: Higher risk of respiratory depression. Codeine contraindication in children <12 years and in adolescents 12-18 years after tonsillectomy/adenoidectomy due to CYP2D6 variability. Tramadol also discouraged in young children.
- Adjuvants: Limited evidence, caution with off-label use.
Geriatric:
- "Start low, go slow": Increased sensitivity to analgesics due to altered pharmacokinetics (decreased renal/hepatic function, decreased body water, increased fat) and pharmacodynamics.
- Polypharmacy: High risk for drug-drug interactions.
- BEERS Criteria: Avoid or use with caution: NSAIDs (GI, renal, CV risk), specific opioids (e.g., meperidine due to neurotoxic metabolite), TCAs (anticholinergic effects, orthostatic hypotension), skeletal muscle relaxants.
- Increased risk of falls: Sedation, dizziness from opioids and gabapentinoids.
- Cognitive impairment: Can affect pain reporting and adherence.
Pregnancy:
- Acetaminophen: Generally considered safe and first-line for pain and fever.
- NSAIDs: Avoid in the third trimester due to risk of premature closure of ductus arteriosus and potential renal dysfunction in the fetus. Caution in first and second trimesters.
- Opioids: Potential for neonatal opioid withdrawal syndrome (NOWS) with prolonged use. Codeine, oxycodone generally considered category C. Use judiciously for severe pain.
- Adjuvants: Many are Category C or D; avoid or use with extreme caution after careful risk-benefit assessment.
Comorbidities:
- Renal Impairment: Avoid/reduce dose of NSAIDs (risk of AKI), gabapentinoids, opioids (accumulation of parent drug and active metabolites). Use acetaminophen cautiously.
- Hepatic Impairment: Avoid/reduce dose of acetaminophen (risk of liver failure), NSAIDs (impaired metabolism, coagulopathy risk), opioids (impaired metabolism, increased sedation).
- Cardiovascular Disease: Avoid/use extreme caution with NSAIDs (increased risk of MI, stroke, heart failure exacerbation).
- Substance Use Disorder (SUD): Careful risk assessment and monitoring for all analgesics, especially opioids. Consider non-opioid strategies, addiction specialist consultation, and close monitoring.
- Psychiatric Disorders: Depression, anxiety can exacerbate pain. TCAs/SNRIs may treat both pain and underlying mood disorder. Opioids can worsen depression.

Clinical Pearls

Diagnostic:
- Pain is subjective: Believe the patient's report of pain.
- Comprehensive pain assessment is key: PQRST, functional impact, psychosocial factors.
- Differentiate pain types: Nociceptive (somatic/visceral) vs. neuropathic vs. nociplastic, as this guides treatment selection.
- Screen for red flags: Rule out urgent underlying pathology.
Treatment:
- Multimodal analgesia: Combining different classes (e.g., acetaminophen + NSAID + adjuvant) targets multiple pain pathways, provides superior analgesia with lower doses of individual agents, and reduces side effects.
- Individualize therapy: No "one size fits all." Consider patient comorbidities, preferences, and goals.
- Titrate slowly: Especially for opioids and adjuvants, to balance efficacy with tolerability.
- Anticipate and proactively manage side effects: e.g., prophylactic laxatives for opioid-induced constipation.
- Set realistic expectations: Complete pain eradication may not be achievable or desirable; focus on functional improvement and tolerable pain levels.
- Educate patients: About their pain, medications, expected effects, side effects, and non-pharmacological strategies.
- Consider dose equivalence: When switching between opioids, use conversion tables cautiously and reduce calculated dose by 25-50% for incomplete cross-tolerance.
Pitfalls:
- Under-treatment of pain: Leads to prolonged suffering, poor outcomes, and central sensitization.
- Over-treatment/Inappropriate prescribing: Especially with opioids, contributes to adverse effects, dependence, and OUD.
- Failure to monitor: Not regularly assessing efficacy and side effects.
- Ignoring psychosocial factors: Pain is a biopsychosocial phenomenon; neglecting psychological distress, sleep disturbances, or social isolation can hinder pain management.
- Fear of addiction: While a valid concern, it should not lead to withholding appropriate pain relief, especially in acute or cancer pain. Responsible prescribing and monitoring are key.
- Using NSAIDs long-term without gastroprotection: Increases risk of GI complications.

Recent Updates

Guidelines:
- CDC Opioid Prescribing Guidelines (2016, 2022): Emphasize non-opioid therapies, lowest effective doses, short durations for acute pain, careful risk assessment, and monitoring for chronic pain. The 2022 update provides more flexibility and less strict dose thresholds than the 2016 version.
- American Pain Society (APS) / American Academy of Pain Medicine (AAPM): Consistently advocate for multimodal, interdisciplinary approaches for chronic pain.
- European League Against Rheumatism (EULAR): Updated guidelines for pain management in specific rheumatologic conditions, often advocating for NSAIDs, disease-modifying antirheumatic drugs (DMARDs), and targeted biological therapies over systemic opioids.
Evidence:
- Growing evidence for non-pharmacological therapies: Robust support for exercise, CBT, and mindfulness in chronic pain management.
- Focus on perioperative pain management: Enhanced Recovery After Surgery (ERAS) protocols emphasize multimodal, opioid-sparing analgesia, often integrating regional blocks, acetaminophen, NSAIDs, and gabapentinoids.
- Development of novel non-opioid agents: Research into nerve growth factor (NGF) inhibitors (e.g., tanezumab) for osteoarthritis, although safety concerns (e.g., rapidly progressive osteoarthritis) have limited widespread adoption. Voltage-gated sodium channel blockers are also in development.
- Precision Pain Medicine: Emerging field leveraging genetics and biomarkers to personalize analgesic selection.
Controversies:
- Role of opioids in chronic non-cancer pain: Balancing pain relief with risks of OUD, overdose, and long-term adverse effects remains a significant challenge and subject of ongoing debate.
- Medical Cannabis for pain: Varying legal status and insufficient robust clinical trial evidence hinder widespread, guideline-based recommendations, despite increasing patient interest.
- Optimal management of opioid-induced hyperalgesia: Difficult to diagnose and manage, often requiring opioid rotation or discontinuation.

Key References

Guidelines:
- World Health Organization (WHO) Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. (2018).
- Centers for Disease Control and Prevention (CDC) Clinical Practice Guideline for Prescribing Opioids for Pain. (2022).
- American Pain Society (APS) and American Academy of Pain Medicine (AAPM) Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. (2009, though many concepts remain relevant).
- National Institute for Health and Care Excellence (NICE) guidelines for chronic pain (primary and secondary care). (2021).
- American College of Rheumatology (ACR) Guidelines for the Management of Osteoarthritis of the Hand, Hip, and Knee. (Updated periodically).
Studies:
- Landmark studies on NSAID GI and CV safety: e.g., PRECISION trial, VIGOR trial, APPROVe trial (related to COX-2 inhibitors).
- Evidence for gabapentinoids in neuropathic pain: Numerous randomized controlled trials.
- Studies on multimodal analgesia in perioperative settings (ERAS protocols).
Reviews:
- Cochrane Reviews on various analgesic interventions (e.g., "Opioids for chronic noncancer pain," "Anticonvulsants for neuropathic pain").
- UpToDate, DynaMed, BMJ Best Practice comprehensive reviews on pain management and pharmacology.